Renaissance Capital logo

Gelteq Priced, Nasdaq: GELS

Australian developer of gel-based formulations of drugs, nutrients, and pet care products.

Industry: Health Care

Latest Trade: $1.83 0.00 (0.0%)

First Day Return: -26.5%

Return from IPO: -54.3%

Industry: Health Care

We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. A “white label” gel-based delivery solution is where we produce a product that other companies rebrand as their own product. Our principal products are edible gels, which we refer to as gels, and their application in gel-based dosage forms. Our current product suite consists of multiple products that sit within five core verticals — for pets, sports, pharmaceutical (pharma), over-the-counter (OTC) and nutraceutical — all of which leverage our patent pending multiple-ingredient dosage forms, and that we expect to have a wide range of applications and consumers. We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license (“white label”).
more less
IPO Data
IPO File Date 07/12/2024
Offer Price $4.00
Price Range $5.00 - $5.00
Offer Shares (mm) 1.3
Deal Size ($mm) $5
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/28/2024
Offer Price $4.00
Price Range $5.00 - $5.00
Offer Shares (mm) 1.3
Deal Size ($mm) $5
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
The Benchmark Company
Company Data
Headquarters Melbourne, Australia
Founded 2018
Employees at IPO n/a
Website www.gelteq.com

Gelteq (GELS) Performance